{"id":"W3172376856","doi":"10.1200/jco.2021.39.15_suppl.2513","title":"ARTISTRY-1: Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre hospitalier universitaire de Québec; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Royal Victoria Hospital; McGill University Health Centre; University of Alberta; Royal Victoria Regional Health Centre","funders":"","keywords":"Medicine; Pembrolizumab; Chills; Internal medicine; Melanoma; Renal cell carcinoma; Adverse effect; Response Evaluation Criteria in Solid Tumors; Tolerability; Gastroenterology; Aldesleukin; Toxicity; Oncology; Phases of clinical research; Surgery; Interleukin 2; Cytokine; Immunotherapy; Cancer; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004383798,0.0004254756,0.0008227877,0.0002809804,0.0002345841,0.0005057587,0.0003725762,0.0005750505,0.002372573],"category_scores_gemma":[0.0003870532,0.0002101993,0.0004696328,0.00030724,0.0003053315,0.0004159761,0.0002582734,0.001032569,0.0005007694],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007109732,"about_ca_system_score_gemma":0.0006730176,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006346451,"about_ca_topic_score_gemma":0.002260963,"domain_scores_codex":[0.9998397,0.00005953689,0.00001182175,0.00003540973,0.00001913032,0.00003439752],"domain_scores_gemma":[0.9997942,0.00003214971,0.00003770296,0.000008958715,0.000008794157,0.000118256],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5479926,0.02811081,0.05026766,0.001205639,0.001442823,0.001483028,0.000428363,0.004140781,0.07276476,0.0003215099,0.009136755,0.2827052],"study_design_scores_gemma":[0.210155,0.5883763,0.1576654,0.000211957,0.0014116,0.002783351,0.0002867671,0.003624182,0.01345982,0.0003359845,0.02161793,0.00007176572],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9935342,0.003318587,0.000112256,0.0002901549,0.00004998395,0.0002709818,0.0004684816,0.00002677883,0.001928666],"genre_scores_gemma":[0.9961351,0.001493818,0.0003113324,0.0002872747,0.00006839932,0.0001599496,0.0006747997,0.000005257972,0.0008641123],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002372573,"threshold_uncertainty_score":0.007937014,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03361205118455683,"score_gpt":0.3936374816355411,"score_spread":0.3600254304509842,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}